Document is current
Any future updates will be listed below
-
Authors
Jiang, Jingjing
Morrell, Liz https://orcid.org/0000-0001-6382-1795
Tungu, Malale
Mawalla, William F.
Chamba, Clara
Chirande, Lulu
Kashaigili, Heronima J.
Mkwizu, Elifuraha
Ntemi, Paul S.
Sandi, Godlove
Schroeder, Kristin
Schuh, Anna
Ruhago, George M.
Wordsworth, Sarah
,
Achola, Caroline
Atim, Pamela
Burns, Adam
Chamba, Clara
Chirande, Lulu
Chiwanga, Faraja
Cutts, Anthony
Dreau, Helene
El Mouden, Claire
Elias, Edrick M.
Goodluck, Philomena
Henke, Oliver
Howard, Kieran
Jennings, Daisy
Josephat, Emmanuel
Kahakwa, Atukuzwe
Kaliisa, Hadija
Kamanga, Jacqueline
Legason, Ismail D.
Leonte, Mihaela
Pascua, Laura Lopez
Magorosa, Erick
Mahawi, Salama
Mapendo, Priscus
Mawalla, William F.
Mbulaiteye, Sam M.
Mbwambo, Daniel
Mkwizu, Elifuraha
Mnango, Leah
Mremi, Alex
Mwamtemi, Hadija
Mwita, Liberata
Ogwang, Martin D.
Otim, Isaac
Ridout, Kate
Sandi, Godlove
Sangeda, Raphael
Scanlan, Patricia
Schroeder, Kristin
Schuh, Anna
Shungu, Rehema
Ntemi, Paul Shadrack
Tungu, Malale
Vavoulis, Dimitris
Wordsworth, Sarah
-
Funding
Funding for this research was provided by:
National Institute for Health and Care Research (NIHR-RIGHT award 200133)
National Institute for Health and Care Research Oxford Biomedical Research Centre
- License Information
-
More Information
Article History
Received: 21 August 2025
Accepted: 4 February 2026
First Online: 21 February 2026
Declarations
:
: Ethics approval for the diagnostic validation study was obtained from Oxford University Tropical Research Ethics Committee (OxTREC 15–19), National Institute of Medical Research (NIMR/HQ/R.8a/Vol.IX/3408) in Tanzania, Uganda National Council of Science and Technology (UNCST, HS529ES), and Lacor Hospital Institutional Research Ethics Committee (074/05/19) in Uganda. Informed consent was provided for all patients. No additional approvals or consent were provided for this economic analysis.
: Not applicable.
: AS has received honoraria in the past 5 years from Oxford Nanopore Technology, Illumina, Exact Sciences, AbbVie, AstraZeneca, BeiGene, and Janssen; is a director and shareholder of SerenOx, an Oxford University social enterprise spin-off; and receives unrestricted research grants from AstraZeneca and Janssen. WFM is a shareholder of SerenOx, and a director and a shareholder of SerenOx Africa Limited, a SerenOx partner company in Tanzania. CC is a director and shareholder of SerenOx Africa Limited. Roche Kenya supported commercial supplies of rituximab, but had no involvement in the design, conduct, analysis or reporting of findings.
